Clopidogrel

Primary Uses

Clopidogrel is primarily prescribed to reduce the risk of heart attack, stroke, or death in individuals who have a history of certain cardiovascular conditions. It is often used for people who have:

• Recently experienced a heart attack or a stroke.
• Been diagnosed with peripheral arterial disease, which is a condition involving poor circulation in the legs.
• Unstable angina (severe chest pain).

Procedures and Stents

This medication is frequently used for patients who have undergone certain heart procedures. For example, it is commonly prescribed after the placement of a coronary stent to help keep the blood vessel open and prevent a clot from forming within the device.

Combination Therapy

In many cases, clopidogrel is used in combination with aspirin. This dual therapy is often recommended for people with acute coronary syndrome or those who have recently received a stent to provide additional protection against blood vessel blockages.

Mechanism of Action

Clopidogrel works by preventing certain blood cells, called platelets, from clumping together. Platelets are small cells that the body uses to form clots and stop bleeding. However, in people with certain heart or blood vessel conditions, these clots can form inside the arteries and block blood flow to the heart or brain.

This medication specifically blocks a chemical signal that platelets need to stick to one another. By interfering with this process, clopidogrel makes the platelets less sticky, which helps keep the blood flowing smoothly through the body.

Key aspects of how it works include:

• Prevention of Clots: It reduces the risk of serious cardiovascular events, such as heart attacks or strokes, by stopping new clots from forming in narrowed blood vessels.
• Long-lasting Effect: Once clopidogrel affects a platelet, that platelet remains less sticky for the rest of its life, which is usually about 7 to 10 days.
• Activation: The body must process clopidogrel into its active form before it can begin working to prevent clots.

Common Side Effects

• Easy bruising or minor bleeding, such as nosebleeds
• Stomach pain, indigestion, or diarrhea
• Headache or dizziness
• Tiredness

Serious Side Effects

Seek medical attention immediately if you experience any of the following:

• Severe or uncontrollable bleeding
• Black, tarry, or bloody stools
• Blood in the urine
• Coughing up blood or vomit that looks like coffee grounds
• Signs of a rare but serious blood disorder called thrombotic thrombocytopenic purpura (TTP), such as fever, extreme weakness, pale skin, purple spots on the skin, or yellowing of the eyes or skin
• Signs of an allergic reaction, including rash, hives, or swelling of the face, lips, or tongue
• Sudden changes in vision, speech, or coordination

Boxed Warning: Genetic Metabolism

Clopidogrel carries a boxed warning because its effectiveness depends on conversion to an active metabolite by the CYP2C19 enzyme in the liver. Individuals with certain genetic variations, known as poor metabolizers, may not receive the full benefit of the medication, increasing their risk of cardiovascular events such as heart attack or stroke. Healthcare providers may use genetic testing to determine if this medication is appropriate.

Bleeding Risks

This medication increases the risk of serious and potentially fatal bleeding. It is not used in individuals with active pathological bleeding, such as a stomach ulcer or bleeding within the skull. Caution is necessary for those with a history of bleeding disorders or those taking other medications that affect blood clotting, such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), or warfarin.

Discontinuation of Treatment

Stopping clopidogrel prematurely can lead to an increased risk of blood clots, heart attack, or stroke, particularly in patients with recently placed coronary stents. Treatment is typically continued as directed by a healthcare provider to prevent these complications.

Thrombotic Thrombocytopenic Purpura (TTP)

A rare but serious condition called TTP has been reported, sometimes shortly after starting clopidogrel. This condition involves the formation of blood clots in small blood vessels, which can lead to low platelet counts and damage to red blood cells. Symptoms requiring immediate medical attention include fever, extreme weakness, pale skin, or purple spots on the skin.

Drug Interactions

Certain drugs can reduce the effectiveness of clopidogrel. Specifically, the use of proton pump inhibitors such as omeprazole or esomeprazole is generally avoided while taking this medication, as they can prevent clopidogrel from being converted into its active form.

Surgery and Procedures

Because clopidogrel affects platelets for several days, it is often necessary to stop the medication five days before elective surgery to reduce the risk of excessive bleeding during the procedure.

Pregnancy

There is limited information about the safety of clopidogrel during pregnancy because well-controlled studies in humans have not been conducted. Animal studies have not shown evidence of harm to the fetus, but these results do not always reflect how the drug will affect humans. Clopidogrel should be used during pregnancy only if a healthcare provider determines it is clearly necessary.

Breastfeeding

It is unknown if clopidogrel passes into human breast milk. Research in animals has shown that the drug is present in milk, which raises concerns about potential side effects for a nursing infant. Patients should discuss with their healthcare provider whether to stop breastfeeding or stop taking the medication, based on the clinical need for the treatment.

Available Forms

Clopidogrel is available as a film-coated tablet for oral use. It is typically taken by mouth once daily, with or without food.

FDA Approval and Indications

Clopidogrel is approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of heart attack, stroke, or cardiovascular death in patients with recent heart attack, recent stroke, or established peripheral arterial disease. It is also indicated for patients with acute coronary syndrome (ACS), including those who are managed medically or with a percutaneous coronary intervention (PCI).

Boxed Warning

The FDA has issued a boxed warning for clopidogrel because its effectiveness depends on its conversion to an active form by the liver enzyme CYP2C19. Some individuals, known as poor metabolizers, have genetic variations that prevent the drug from being fully activated. This can result in reduced antiplatelet activity and a higher risk of cardiovascular events. Healthcare providers may use genetic testing to determine if a patient is a poor metabolizer and consider alternative treatments if necessary.

Safety Communications

The FDA has conducted safety reviews regarding the long-term use of clopidogrel. A review of the Dual Antiplatelet Therapy (DAPT) trial concluded that long-term treatment with clopidogrel (30 months) did not increase the risk of death compared to shorter treatment durations (12 months). Additionally, the FDA has issued warnings about potential drug interactions, specifically noting that certain proton pump inhibitors, such as omeprazole or esomeprazole, can reduce the effectiveness of clopidogrel by interfering with the enzyme that activates the drug.

FDA-Approved Indications

The U.S. Food and Drug Administration (FDA) has approved clopidogrel for use in patients with the following conditions:

• Recent heart attack or recent stroke.
• Established peripheral arterial disease (a condition involving poor circulation in the legs).
• Acute coronary syndrome (ACS), including unstable angina or certain types of heart attacks, often in combination with aspirin.

Boxed Warning

Clopidogrel carries an FDA boxed warning regarding its effectiveness in certain individuals. The medication must be converted into its active form by a specific liver enzyme called CYP2C19. Some people have genetic variations that make them "poor metabolizers" of the drug, meaning it may not work effectively to prevent blood clots. Healthcare providers may perform genetic testing to determine if clopidogrel is appropriate for a patient or if an alternative treatment is necessary.

Safety and Interactions

The FDA warns that clopidogrel increases the risk of serious and potentially life-threatening bleeding. Additionally, the FDA advises against using clopidogrel with certain proton pump inhibitors (PPIs), such as omeprazole or esomeprazole. These medications can block the enzyme that activates clopidogrel, making it less effective at preventing heart attacks and strokes.